Metabolomic Laboratory-Developed Tests: Current Status and Perspectives
نویسندگان
چکیده
منابع مشابه
Regulating laboratory-developed tests.
Disclaimer: The views expressed in this editorial are solely those of the author and should not be construed as reflecting the views of the Department of Veterans Affairs or the United States Government. As a molecular pathologist for more than 20 years, I have had the opportunity to develop laboratory tests and to assess the efforts of others to develop laboratory tests. As Editor of The Journ...
متن کاملDown Syndrome: Current Status, Challenges and Future Perspectives
Down syndrome (DS) is a birth defect with huge medical and social costs, caused by trisomy of whole or part of chromosome 21. It is the most prevalent genetic disease worldwide and the common genetic cause of intellectual disabilities appearing in about 1 in 400-1500 newborns. Although the syndrome had been described thousands of years before, it was named after John Langdon Down who described ...
متن کاملThe long and winding regulatory road for laboratory-developed tests.
"High complexity" clinical laboratories are approved under the Clinical Laboratory Improvement Amendments to develop, validate, and offer a laboratory-developed test (LDT) for clinical use. The Food and Drug Administration considers LDTs to be medical devices under their regulatory jurisdiction, and that at least certain LDTs should be subject to greater regulatory scrutiny. This review describ...
متن کاملdown syndrome: current status, challenges and future perspectives
down syndrome (ds) is a birth defect with huge medical and social costs, caused by trisomy of whole or part of chromosome 21. it is the most prevalent genetic disease worldwide and the common genetic cause of intellectual disabilities appearing in about 1 in 400-1500 newborns. although the syndrome had been described thousands of years before, it was named after john langdon down who described ...
متن کاملRegulating laboratory-developed tests: devil will be in details.
For 2 days in January, the National Institutes of Health was the epicenter of the debate that has swirled around laboratory-developed tests (LDTs) since last July, when the U.S. Food and Drug Administration announced it would begin regulating them. More than 80 people—representing pathologists , clinicians, patients, and laborato-ries—spoke during FDA's unusually large and long public workshop....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Metabolites
سال: 2021
ISSN: 2218-1989
DOI: 10.3390/metabo11070423